1. BEHAVIOR AND MEMORY EVALUATION OF RATS TREATED WITH SIMVASTATIN IN THE SCOPOLAMINE ANIMAL MODEL TONIN, F. S.; BARBIERO, J. K. Departamento de Farmacologia, Laboratório de Fisiologia e Farmacologia do Sistema Nervoso Central, Universidade Federal do Paraná, Curitiba/PR, Brazil
INTRODUCTION
OBJECTIVES
METHODS
RESULTS
Fig 4, 5. No significant differences in any parameter evaluated in OP. Number of avoidances decrease in CMC+Scopolamine group. Values: p<0.01 (**) compared CMC+Scopolamine and CMC+Saline; p<0.01 ($$)compared CMC+Scopolamine and CMC+Simvastatin; p<0.05 (#) compared CMC+Scopolamine and Simvastatin+Saline
CONCLUSIONS
REFERENCES
Although the pathophysiology of Alzheimer disease (AD) is not yet fully elucidated, it is associated with neurodegeneration in brain areas involved with learning and memory. Some studies demonstrated a lower risk for AD by using statins. In this context, animal models represent a useful tool for the comprehension of AD pathways.1,2
OPEN FIELD AND TWO-WAY ACTIVE AVOIDANCE
Determine whether prolonged administration of simvastatin in rats is able to protect against memory deficits caused by scopolamine.
Animals divided into groups
Treatment started
Day 1
Morris Water Maze (MWM) training
Day 7-11
Open Field Test
MWM Test
Two-Way Active Avoidance (TW) training
Day 12
Two-Way Active Avoidance (TW) Test
Day 13
Fig. 1 Experimental procedures
Scopolamine (1.0 mg/kg) or saline 0.9% (i.p.)
MORRIS WATER MAZE
During Days 1-11:
Simvastatin (10.0 mg/kg)
or CMC (gavage)
Fig 6, 7. During training MWM, CMC+Scopolamine group showed an increase in the latency time, statistically significant from day 9 (p <0.0001). In the test (day 12), stayed percentage of the platform quadrant (2) was different between CMC+Scopolamine and other groups (**p < ) .
Fig. 3 Morris Water Maze (MWM)
Scopolamine impaired the memory acquisition of rats in TW and MWM tasks. The previous and prolonged administration of simvastatin was able to protect the animals against these effects without affecting motor behavior.
Fig. 2 Open Field (OP)
1 KLINKENBERG, I.; BLOKLAND A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci. Biobe. 34: 1307, 2010.
2 PARIHAR, M. S.; BREWER, G. J. Amyloid Beta as a Modulator of Synaptic Plasticity. J Alzheimers Dis. 22: 741, 2010.
Fig. 4 Two-Way Active Avoidance (TW)